Development of a SARS coronavirus vaccine from recombinant spike protein plus delta inulin adjuvant

Clifton McPherson, Richard Chubet, Kathy Holtz, Yoshikazu Honda-Okubo, Dale Barnard, Manon Cox, Nikolai Petrovsky

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

18 Citations (Scopus)


Given periodic outbreaks of fatal human infections caused by coronaviruses, development of an optimal coronavirus vaccine platform capable of rapid production is an ongoing priority. This chapter describes the use of an insect cell expression system for rapid production of a recombinant vaccine against severe acute respiratory syndrome coronavirus (SARS). Detailed methods are presented for expression, purification, and release testing of SARS recombinant spike protein antigen, followed by adjuvant formulation and animal testing. The methods herein described for rapid development of a highly protective SARS vaccine are equally suited to rapid development of vaccines against other fatal human coronavirus infections, e.g., the MERS coronavirus.

Original languageEnglish
Title of host publicationVaccine Design: Methods and Protocols Volume 1
Subtitle of host publicationVaccines for Human Diseases
EditorsSunil Thomas
Place of PublicationNew York
PublisherHumana Press Inc.
Number of pages16
ISBN (Electronic)9781493933877
ISBN (Print)9781493933853
Publication statusPublished - 1 Apr 2016

Publication series

NameMethods in Molecular Biology
ISSN (Print)1064-3745
ISSN (Electronic)1940-6029


  • Adjuvant
  • Advax adjuvant
  • Baculovirus
  • CGMP
  • Coronavirus
  • Delta inulin
  • Manufacture
  • MERS
  • SARS
  • Vaccine


Dive into the research topics of 'Development of a SARS coronavirus vaccine from recombinant spike protein plus delta inulin adjuvant'. Together they form a unique fingerprint.

Cite this